Clinical trial
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug…
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159770 |
|---|---|
| Title | Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients |
| Official title | Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical… |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Psychotic Disorders |
| Intervention type | Behavioral, Drug, Procedure |
| Interventions | ziprasidone versus olanzapine, risperidone or quetiapine, Panss, CGI-C, UKU-SERS-Pa, Blood tests |
| Enrollment | 290 |
| Start date | Nov 1, 2001 |
| Completion | Sep 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 21, 2021 |
| Countries | Denmark, Finland, Iceland, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: